Evidence map›Paper›PMID 36131232›Full record

Observational studyBMC infectious diseases2022

Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).

Jessica J Tuan, Heidi Zapata, Lydia Barakat, Laurie Andrews, Anousheh Behnegar, Yee Won Kim, Jehanzeb Kayani, Suzana Mutic, Linda Ryall, Barbara Turcotte and 8 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Jessica J TuanYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA. Jessica.tuan@yale.edu.
Heidi ZapataYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Lydia BarakatYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Laurie AndrewsYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Anousheh BehnegarYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Yee Won KimYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Jehanzeb KayaniYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Suzana MuticYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Linda RyallYale Center for Clinical Investigation, Yale University School of Medicine, 2 Church Street South, Suite 401, New Haven, CT, 06519, USA.
Barbara TurcotteYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Terese Critch-GilfillanYale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT, 06510, USA.
Min ZhaoYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Syim SalahuddinYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Shaili GuptaYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Richard SuttonYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Gerald FriedlandYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Brinda EmuYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Onyema OgbuaguYale University School of Medicine, 333 Cedar Street, PO Box 208022, New Haven, CT, 06510, USA.
Yale University · USVA Connecticut Healthcare System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Single Cell Characterization of Adipose Tissue in the Setting of HIV and AgingK76AG064548 · NIA · YALE UNIVERSITY · PI ZAPATA, HEIDI J · 2019 to 2023
$1.4M
NCATS NIH HHS UL1 TR001863NIA NIH HHS K76 AG064548
6 · The paper itself

Abstract

backgroundThe durability of immune responses to COVID-19 vaccines among older people living with HIV (PWH) is clinically important.

methodsWe aimed to assess vaccine-induced humoral immunity and durability in older PWH (≥ 55 years, n = 26) over 6 months (post-initial BNT162b2 series). A secondary and exploratory objective was to assess T-cell response and BNT162b2 booster reactogenicity, respectively. Our Visit 1 (3 weeks post-initial BNT162b2 dose) SARS-CoV-2 humoral immunity results are previously reported; these subjects were recruited for Visit 2 [2 weeks (+ 1 week window) post-second vaccination] and Visit 3 [6 months (± 2 week window) post-initial vaccination] in a single-center longitudinal observational study. Twelve participants had paired Visit 2/3 SARS-CoV-2 Anti-Spike IgG data. At Visit 3, SARS-CoV-2 Anti-Spike IgG testing occurred, and 5 subjects underwent T-cell immune response evaluation. Thereafter, subjects were offered BNT162b2 booster (concurrent day outside our study) per US FDA/CDC guidance; reactogenicity was assessed. The primary study outcome was presence of detectable Visit 3 SARS-CoV-2 Anti-Spike-1-RBD IgG levels. Secondary and exploratory outcomes were T-cell immune response and BNT162b2 booster reactogenicity, respectively. Wilcoxon signed-rank tests analyzed median SARS-CoV-2 Anti-Spike IgG 6-month trends.

resultsAt Visit 3, 26 subjects underwent primary analysis with demographics noted: Median age 61 years; male n = 16 (62%), female n = 10 (38%); Black n = 13 (50%), White n = 13 (50%). Most subjects (n = 20, 77%) had suppressed HIV viremia on antiretroviral therapy, majority (n = 24, 92%) with CD4 > 200 cells/µL. At Visit 3, 26/26 (100%) had detectable Anti-Spike-1-RBD (≥ 0.8 U/mL). Among 12 subjects presenting to Visit 2/3, median SARS-CoV-2 Anti-Spike 1-RBD was 2087 U/mL at Visit 2, falling to 581.5 U/mL at Visit 3 (p = 0.0923), with a median 3.305-fold decrease over 6 months. Among subjects (n = 5) with 6-month T-cell responses measured, all had detectable cytokine-secreting anti-spike CD4 responses; 3 had detectable CD4 + Activation induced marker (AIM) + cells. Two had detectable cytokine-secreting CD8 responses, but all had positive CD8 + AIM + cells.

conclusionsAmong older PWH, SARS-CoV-2 Anti-Spike IgG and virus-specific T-cell responses are present 6 months post-primary BNT162b2 vaccination, and although waning, suggest retention of some degree of long-term protective immunity.

Indexed as

COVID-19Viral VaccinesAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesCytokinesFemaleHumansImmunoglobulin GMaleMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesCytokinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral VaccinesBNT162b2COVID-19HIVImmunogenicitySARS-CoV-2

Identifiers

PMID36131232
PMCPMC9491266
OpenAlexW4296711205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.